Attention bias toward noncooperative people. A dot probe classification study in cheating detection

Anellid

Laser-Induced Smoke in Dermatologic Practice: A Survey to Explore Hazard Perceptions, Safety Measures and Unmet Needs : Laser-Induced Smoke Study

Introduction: Inhalation of laser-induced smoke is a potential health hazard to exposed physicians and laser operators. To date, little is known about the perception of health hazards related to laser-induced smoke exposure among physicians and the actual use of safety measures to mitigate these risks.Methods: In May 2020, 514 members of the European Society for Lasers and Energy-Based Devices (ESLD) were invited by email to participate in an online survey. The survey comprised 16 questions including multiple-choice and open-ended questions.Results: Responses were received from 109 participants. The majority (90%) were aware of potential hazards and highlighted a desire for better protective measures (60%). A smoke evacuation system was frequently used with ablative lasers (66%) and fractional ablative lasers (61%), but less the case with non-ablative lasers (30%) and hair removal lasers (28%). The COVID-19 outbreak had no clear effect on the use of smoke evacuation systems. Prior to the COVID-19 outbreak, mainly surgical masks were used (40-57%), while high filtration masks (FFP1, FFP2 or FFP3) were used by only a small percentage (15-30%). The post-COVID-19 outbreak, the use of high filtration masks increased significantly (54-66%), predominately due to an increase in the use of FFP2 masks. Reasons mentioned for inadequate protective measures were sparse knowledge, limited availability, discomfort, excessive noise, high room temperatures, and financial costs.Conclusion: While there is considerable awareness of the hazards of laser-induced smoke among physicians and laser operators, a substantial number of them do not use appropriate protective measures. The implementation of regulations on safety measures is hampered by sparse knowledge, limited availability, discomfort, excessive noise, financial issues, and high room temperature

Identification of elite performance characteristics in a small sample of taekwondo athletes

Along with the increasing popularity of taekwondo, there is a need of evidence-based talent identification (TID) and development programs based upon profiles of future elite athletes. This study first aims to investigate the differences between elite and non-elite taekwondo athletes in anthropometry, physical performance and motor coordination. The second aim is to demonstrate the applicability of z-scores in TID research. A total of 98 Taekwondo athletes between 12 and 17 years old were tested using a generic test battery consisting of four anthropometrical (Height, Weight, Fat Percentage, BMI), six physical performance (Sit & Reach, Sprint 5m, Sprint 30m, Counter Movement Jump, Squat Jump, Endurance Shuttle Run) and three motor coordination tests (Moving Sideways, Jumping Sideways, Walking Backwards). Based on the individual success at international competition level, 18 were categorised as elite athletes and 80 were considered as non-elite. T-tests (step 1) on raw test scores and MANOVAs on z-scores (step 2) were conducted to examine differences between the elite and non-elite taekwondo athletes for anthropometry, physical performance and motor coordination tests. Finally, z-scores were reconverted to raw scores to demonstrate practical significance for coaches. Overall, elite taekwondo athletes score better compared to the non-elite group. The MANOVA analysis better scores for elites on fat percentage (-0.55 versus 0.12;p = 0.006), BMI (-0.37 versus 0,08;p = 0.067) sprint speed 30m (-0.48 versus 0.11;p = 0.029), counter movement jump (0.79 versus -0.18;p = 0.000), squat jump (0.42 versus -0.11;p = 0.041), moving sideways (0.79 versus -0.18;p = 0.000) and walking backwards (0.54 versus -0.12;p = 0.006). This study confirms our knowledge on physical profiles of elite taekwondo athletes and expands our knowledge to the domain of motor coordination. This study showed how the z-score method can be used to distinguish between elite and non-elite athletes, the former being low in number by definition

Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months:an observational multi-center study

Observational studies of up to 12 months duration showed that glatiramer acetate (GA) treatment of relapsing-remitting multiple sclerosis may result in decreased fatigue and improves health-related quality of life (HRQoL), with no changes in disability or mood. We investigated whether in the second year of treatment these improvements are sustained, disability or mood yet improved, and 2-year changes may be predicted by changes in the first 6 or 12 months. The multi-center FOCUS-Extension study was a prospective extension of the 12-month, international, observational FOCUS study and included 67 patients (38 treatment-na <ve, 29 pre-treated) of the Dutch FOCUS cohort. Fatigue, HRQoL, depression and disability were measured by the Fatigue Impact Scale (FIS), Leeds Multiple Sclerosis Quality of Life (LMSQoL) questionnaire, Beck Depression Inventory-Short Form and the Guy's Neurological Disability Scale. A 2-year period of GA treatment was associated with -0.52 and +0.66 standard deviation changes in mean FIS and LMSQoL scores compared to baseline, whereas disability and mood remained unchanged. For FIS and LMSQoL, the Pearson correlation coefficients between 6-month changes and 2-year scores were 0.47 and 0.50, and between 12-month changes and 2-year scores 0.65 and 0.62. After 2 years GA treatment, the improvements in fatigue and HRQoL observed at 1 year are sustained, whereas disability and mood remain unchanged compared to baseline. Moreover, the levels of fatigue and HRQoL at 2 years GA treatment are predicted by the improvements at 6 months

Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months:an observational multi-center study

Observational studies of up to 12 months duration showed that glatiramer acetate (GA) treatment of relapsing-remitting multiple sclerosis may result in decreased fatigue and improves health-related quality of life (HRQoL), with no changes in disability or mood. We investigated whether in the second year of treatment these improvements are sustained, disability or mood yet improved, and 2-year changes may be predicted by changes in the first 6 or 12 months. The multi-center FOCUS-Extension study was a prospective extension of the 12-month, international, observational FOCUS study and included 67 patients (38 treatment-na <ve, 29 pre-treated) of the Dutch FOCUS cohort. Fatigue, HRQoL, depression and disability were measured by the Fatigue Impact Scale (FIS), Leeds Multiple Sclerosis Quality of Life (LMSQoL) questionnaire, Beck Depression Inventory-Short Form and the Guy's Neurological Disability Scale. A 2-year period of GA treatment was associated with -0.52 and +0.66 standard deviation changes in mean FIS and LMSQoL scores compared to baseline, whereas disability and mood remained unchanged. For FIS and LMSQoL, the Pearson correlation coefficients between 6-month changes and 2-year scores were 0.47 and 0.50, and between 12-month changes and 2-year scores 0.65 and 0.62. After 2 years GA treatment, the improvements in fatigue and HRQoL observed at 1 year are sustained, whereas disability and mood remain unchanged compared to baseline. Moreover, the levels of fatigue and HRQoL at 2 years GA treatment are predicted by the improvements at 6 months